ProCE Banner Activity

CONTACT-02: Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Conference Coverage

Treatment with cabozantinib plus atezolizumab resulted in a significantly longer PFS vs a second novel hormonal therapy in patients with mCRPC with progressive disease after a first novel hormonal therapy in the phase III CONTACT-02 trial.

Released: January 31, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC